TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > Six uncomfortable regulatory truths in a pandemic

Six uncomfortable regulatory truths in a pandemic

Six

Author: Arthur Brandwood

These are truly extraordinary times. With supply chains breaking down and demand outstripping supply for critical products such as ventilators, masks and test kits, both regulators and industry are having to do things very differently. But amongst all of the panic and all of the generously volunteered goodwill, it’s important to keep some rigour and structure amongst the chaos. Here are six things that should be front of mind for regulators and manufacturers alike.

1. Regulators still need to regulate – but fast

A typical regulatory review time for a Ventilator or a Class 3 IVD can be six months to a year or more, depending on the market and the agency.

That just won’t cut it right now.

So regulators are bending rules as much as they can. But it’s really important that they don’t break the rules. History shows that rushed decisions in emergencies can do more harm than good. Who remembers tainted blood scandals with imperfect screening in the HIV pandemic? Just yesterday it emerged that some Conavirus tests distributed by the US CDC were faulty. Luckily the problem was picked up quickly by the State public health labs and is being fixed, after some regulatory gymnastics from FDA to allow state labs to participate in reagent development – but it all takes precious time.

Australia’s TGA is approving COVID-19 tests based on less evidence than perhaps might have been the case in the normally rigorous, meticulous TGA process, but they still require evidence that provides a reasonable assurance of safety and performance for emergency use.

Which brings me to…

2. Risk Benefit balance still applies – but hey, ventilators keep you breathing

Not breaking regulatory rules means still focusing on the patient risks vs. clinical benefits. Now regulators (and the rules they work within) tend towards risk aversion. But hey, when the choice is between a kludged together ventilator from an automotive factory and no ventilator at all, it’s pretty clear there’s still a net patient benefit. It’s good to see the UK MHRA convening expert advisors to figure out quickly just what the truly essential requirements are for a ventilator, and the US FDA relaxing rules on design change notifications to allow ventilator manufacturers flexibility on component sourcing as they ramp up production.

3. Time is precious

Regulators are overloaded with all of this, and right now their time is precious. And every man and his dog are calling up their national regulator or health department with offers of devices and test kits which may help. This is all very well intentioned. But before seeking that urgent pre-consultation, ask yourself: “do I really have something right now that’s backed with sufficient evidence to pass even an expedited and streamlined emergency review?” If not, then perhaps it’s better to keep out of the way.

4. Trust is a lubricant

There’s a fascinating story in Malcolm Gladwell’s book The Tipping Point about how Toyota’s over-lean, just-in-time, supply chain almost brought the car giant undone as a factory fire took out the single source of brake valves for all of the company’s cars and light trucks. Toyota re-established production in just two weeks and was back up to full scale in around a month. This was done with the help of direct competitors and a wide network of contacts including a loan of a production line by Nissan and technical help from sewing machine manufacturers and jewellery technicians. The point was it was done without any written contracts and in a spirit of greater national interest. The whole remarkable exercise worked because of trust. In fearful times, trust is perhaps all too scarce – but it’s needed now more than ever. When working together in a crisis, trust is an essential lubricant.

5. There’s no need to change the rules

Pandemic planning has long been a part of regulators’ strategic outlook. As a result, regulators already have the tools they need to act quickly and prioritise what matters. Here in Australia TGA has powers to expedite reviews, to relax things like restrictions on point of care testing for serious diseases, or to make emergency supply exemptions for unapproved medicines or devices.

There’s generally no need for rule changes.

6. Data really is King

Manufacturers who can contribute to the efforts to defeat the pandemic need to be equally nimble and to understand how to navigate the existing regulatory pathways efficiently.

Most of all, if you seek expedited treatment, be ready to provide the hard data to allow the regulators to do a speedy job.

If you’re considering an approach to any regulator and would like to understand the logistics, the requirements, or you’d just like to better understand your current product, be sure to reach out to us. We’ve got a fantastic team ready to answer any of your questions.

Contact us
Related posts
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
Recent Blogs
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
20h

The #CTIS brings many opportunities, but it will also require a lot of process changes and preparation, find out more 👉https://lnkd.in/eZRqyPPX about the benefits and challenges with the CTIS.

➡  Take the @Phlexglobal #survey! https://lnkd.in/eA5FwHJC

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Provided honest feedback and collaborative working solutions to obstacles

    South Korea based medium sized company
    Manager
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for